Saudi Arabia's Pharma Market Is 'Open For Business'
This article was originally published in Scrip
Executive Summary
Saudi Arabia could be an exciting market for many pharmaceutical companies looking to grow their business. Not only is it the biggest market in the Gulf, worth $5.1bn in 2012, but it is also an important gateway for other markets in a region where demand is steadily growing. And now new developments at the Saudi Food & Drugs Authority (SFDA) means that firms will likely find it easier to get to the market, explains Hassaan Alwohaibi, director of product licensing at the SFDA's drug division.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.